{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027274","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2026-06-04T20:15:33+00:00","discovered_at":"2026-06-04T20:17:00.227710+00:00","generated_at":"2026-06-04T20:50:50.578900+00:00","sec_items":["1.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sanara MedTech terminates Catalyst advisory agreement; shifts to soft tissue/bone fusion strategy","bullets":["On June 2, 2026, Sanara MedTech and The Catalyst Group mutually terminated their March 2023 advisory agreement.","Termination due to shift in strategy to focus on soft tissue repair and bone fusion surgical products.","No fee or penalty paid in connection with termination; certain covenants (indemnification, confidentiality) remain in effect.","Chairman Ronald T. Nixon is founder/managing partner of Catalyst and holds >5% beneficial ownership of Sanara MedTech."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027274","json":"https://secwatch.observer/filing/0001493152-26-027274.json","markdown":"https://secwatch.observer/filing/0001493152-26-027274.md","text":"https://secwatch.observer/filing/0001493152-26-027274.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315226027274/0001493152-26-027274-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315226027274/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:50:50.578900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fbf0325cbed75c69e3c83a861ef597fc6861fb9","claim":"Sanara MedTech Inc. terminated Services Agreement with The Catalyst Group, Inc. (effective 2026-06-02).","evidence_excerpt":"On June 2, 2026, in connection with the Company’s shift in strategy to focus on soft tissue repair and bone fusion products for the surgical market, the Company entered into a Mutual Termination Agreement (the “Mutual Termination Agreement”) with Catalyst, pursuant to which the parties agreed to terminate the Services Agreement, effective immediately.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315226027274/0001493152-26-027274-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Counterparty","value":"The Catalyst Group, Inc."},{"label":"Effective","value":"2026-06-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}